帕博利珠单抗联合聚乙二醇干扰素α-2b治疗晚期黑色素瘤的Ib/II期研究
该Ib/II期研究评估帕博利珠单抗联合聚乙二醇干扰素α-2b在未接受过PD-1抑制剂的晚期黑色素瘤患者中的安全性和疗效。43例患者中客观缓解率为60.5%,中位无进展生存期11.0个月,2年无进展生存率46%,3/4级治疗相关不良事件发生率为48.8%。结论认为该联合方案毒性可接受且显示出有前景的临床疗效。
要点
- 联合方案在未接受PD-1抑制剂的晚期黑色素瘤中客观缓解率达60.5%。
- 中位无进展生存期11.0个月,2年无进展生存率46%。
- 3/4级治疗相关不良事件发生率为48.8%,毒性可接受。
核心结论
- 帕博利珠单抗联合聚乙二醇干扰素α-2b在未接受过PD-1抑制剂的晚期黑色素瘤中显示出可接受的毒性和有前景的临床疗效。
研究设计与样本
- Ib/II期研究,Ib期采用改良毒性概率区间设计对聚乙二醇干扰素α-2b(1、2、3 μg/kg每周)进行剂量递增,帕博利珠单抗固定剂量2 mg/kg每3周;II期入组31例;共43例IV期黑色素瘤患者纳入分析。
主要发现
- 43例可评估患者中客观缓解率为60.5%,46.5%的患者缓解持续。
- 全体患者中位无进展生存期为11.0个月,缓解者中位无进展生存期未达到。
- 全体患者中位总生存期未达到,2年无进展生存率为46%。
- 所有43例患者均发生至少1项不良事件,3/4级治疗相关不良事件发生于21/43例(48.8%)。
临床怎么用
- 该联合方案可作为未接受过PD-1抑制剂的晚期黑色素瘤患者的潜在治疗选择,但需关注3/4级治疗相关不良事件的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Objective responses are reported in 34% to 37% of patients with programmed death-1 (PD-1)-naïve advanced melanoma treated with PD-1 inhibitors. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature correlate with response to PD-1 blockade. Here, we report a phase Ib/II study of pembrolizumab/pegylated (PEG)-IFN combination in PD-1-naïve advanced melanoma. PATIENTS AND METHODS: PEG-IFN (1, 2, and 3 μg/kg per week) was dose escalated using a modified toxicity probability interval design in three cohorts of four patients each, whereas pembrolizumab was dosed at 2 mg/kg every 3 weeks in the phase Ib portion. Thirty-one patients were enrolled in the phase II portion. Primary objectives were safety and incidence of dose-limiting toxicities. Secondary objectives included objective response rate, progression-free survival (PFS), and overall survival. RESULTS: Forty-three patients with stage IV melanoma were enrolled in the phase Ib and II portions of the study and included in the analysis. At the data cutoff date (December 31, 2017), median follow-up duration was 25 months (range, 1 to 38 months). All 43 patients experienced at least one adverse event; grade 3/4 treatment-related adverse events occurred in 21 of 43 patients (48.8%). Objective responses were seen at all three dose levels among 43 evaluable patients. The objective response rate was 60.5%, with 46.5% of patients exhibiting ongoing response. Median PFS was 11.0 months in all patients and unreached in responders, whereas median overall survival remained unreached in all patients. The 2-year PFS rate was 46%. CONCLUSION: Pembrolizumab/PEG-IFN demonstrated an acceptable toxicity profile with promising evidence of clinical efficacy in PD-1-naïve metastatic melanoma. These results support the rationale to further investigate this pembrolizumab/PEG-IFN combination in this disease.
引用
- Davar D, Wang H, Chauvin JM, et al. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018. PMID: 30359157. doi:10.1200/JCO.18.00632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。